Financial Statements of

OTTAWA HOSPITAL RESEARCH INSTITUTE

year ended March 31, 2013
Independent Auditor's Report

To the Members of the Ottawa Hospital Research Institute

We have audited the accompanying financial statements of the Ottawa Hospital Research Institute, which comprise the statement of financial position as at March 31, 2013, and the statements of operations, changes in net assets and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
Independent Auditor's Report (Continued)

Auditor's Responsibility (Continued)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Ottawa Hospital Research Institute as at March 31, 2013 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Comparative Information

Without modifying our opinion, we draw attention to Note 2 to the financial statements which describes that the Ottawa Hospital Research Institute adopted Canadian accounting standards for not-for-profit organizations on April 1, 2012 with a transition date of April 1, 2011. These standards were applied retrospectively by management to the comparative information in these financial statements, including the statements of financial position as at March 31, 2012 and April 1, 2011, and the statements of operations, changes in net assets and cash flows for the year ended March 31, 2012 and related disclosures. We were not engaged to report on the comparative information, and as such, it is unaudited.

Deloitte LLP
Chartered Accountants
Licensed Public Accountants
June 25, 2013
OTTAWA HOSPITAL RESEARCH INSTITUTE
Statement of Financial Position
as at March 31, 2013

<table>
<thead>
<tr>
<th></th>
<th>Externally Restricted</th>
<th>Unrestricted</th>
<th>March 31, 2013</th>
<th>March 31, 2012 (Unaudited)</th>
<th>April 1, 2012 (Unaudited)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$10,698,490</td>
<td>$4,478,090</td>
<td>$15,176,580</td>
<td>$18,656,320</td>
<td>$21,989,147</td>
</tr>
<tr>
<td>Due from The Ottawa Hospital Foundation (Note 4)</td>
<td>1,007,838</td>
<td>3,828,484</td>
<td>4,836,322</td>
<td>3,859,042</td>
<td>2,728,700</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>8,440,282</td>
<td>1,621,382</td>
<td>10,061,664</td>
<td>14,672,885</td>
<td>6,659,428</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>35,888</td>
<td>13,331</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20,146,610</td>
<td>30,074,566</td>
<td>37,224,135</td>
</tr>
<tr>
<td><strong>INVESTMENTS (Note 5)</strong></td>
<td></td>
<td></td>
<td>9,927,956</td>
<td>31,390,606</td>
<td></td>
</tr>
<tr>
<td><strong>CAPITAL ASSETS (Note 6)</strong></td>
<td></td>
<td></td>
<td>10,537,031</td>
<td></td>
<td>99,352,423</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>95,609,075</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
<td>99,346,933</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$1,397,819</td>
<td>$588,065</td>
<td>$1,985,884</td>
<td>$13,648,663</td>
<td>$2,587,718</td>
</tr>
<tr>
<td>Loan payable (Note 4)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>200,000</td>
<td>450,000</td>
</tr>
<tr>
<td>Due to The Ottawa Hospital (Note 4)</td>
<td>3,838,252</td>
<td>3,838,252</td>
<td>1,851,111</td>
<td>1,883,412</td>
<td></td>
</tr>
<tr>
<td>Unearned income</td>
<td>500,000</td>
<td>-</td>
<td>500,000</td>
<td>100,000</td>
<td>780,379</td>
</tr>
<tr>
<td>Unexpended research project funding (Note 7)</td>
<td>67,874,441</td>
<td>-</td>
<td>67,874,441</td>
<td>63,045,498</td>
<td>61,804,689</td>
</tr>
<tr>
<td></td>
<td>69,772,260</td>
<td>4,426,317</td>
<td>74,198,577</td>
<td>78,845,272</td>
<td>67,506,198</td>
</tr>
<tr>
<td><strong>DEFERRED CAPITAL CONTRIBUTIONS (Note 8)</strong></td>
<td>25,031,146</td>
<td>-</td>
<td>25,031,146</td>
<td>25,296,000</td>
<td>27,759,574</td>
</tr>
<tr>
<td>SICK LEAVE (Note 9)</td>
<td>-</td>
<td>117,210</td>
<td>117,210</td>
<td>136,786</td>
<td></td>
</tr>
<tr>
<td></td>
<td>94,803,406</td>
<td>4,543,527</td>
<td>99,346,933</td>
<td>104,258,482</td>
<td>95,402,558</td>
</tr>
<tr>
<td><strong>COMMITMENTS (Note 10)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Internally restricted (Note 11)</td>
<td>-</td>
<td>2,863,437</td>
<td>2,863,437</td>
<td>2,568,047</td>
<td>1,854,961</td>
</tr>
<tr>
<td>Invested in capital assets</td>
<td>805,669</td>
<td>-</td>
<td>805,669</td>
<td>712,761</td>
<td>708,905</td>
</tr>
<tr>
<td>Unrestricted</td>
<td>-</td>
<td>2,520,992</td>
<td>2,520,992</td>
<td>2,613,900</td>
<td>1,385,999</td>
</tr>
<tr>
<td></td>
<td>805,669</td>
<td>5,384,429</td>
<td>-</td>
<td>6,190,098</td>
<td>5,894,708</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$95,609,075</td>
<td>$9,927,956</td>
<td>$105,537,031</td>
<td>$110,153,190</td>
<td>$99,352,423</td>
</tr>
</tbody>
</table>

ON BEHALF OF THE BOARD

[Signatures]

See accompanying notes to the financial statements
## Statement of Operations

**year ended March 31, 2013**

<table>
<thead>
<tr>
<th></th>
<th>Externally</th>
<th>Restricted</th>
<th>Unrestricted</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Unaudited)</td>
<td>(Note 2)</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Ottawa Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation (Note 4):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and salary</td>
<td>$ -</td>
<td>$ 2,128,021</td>
<td>$ 2,128,021</td>
<td>$ 1,861,303</td>
<td></td>
</tr>
<tr>
<td>Endowment fund income</td>
<td>-</td>
<td>2,705,451</td>
<td>2,705,451</td>
<td>2,677,401</td>
<td></td>
</tr>
<tr>
<td>Indirect cost recovery</td>
<td>-</td>
<td>6,890,462</td>
<td>6,890,462</td>
<td>6,552,210</td>
<td></td>
</tr>
<tr>
<td>The Ottawa Hospital (Note 4)</td>
<td>-</td>
<td>4,602,196</td>
<td>4,602,196</td>
<td>5,182,575</td>
<td></td>
</tr>
<tr>
<td>University of Ottawa (Note 4)</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salary support</td>
<td>-</td>
<td>1,222,792</td>
<td>1,222,792</td>
<td>1,368,843</td>
<td></td>
</tr>
<tr>
<td>Endowment fund income</td>
<td>-</td>
<td>152,914</td>
<td>152,914</td>
<td>153,579</td>
<td></td>
</tr>
<tr>
<td>Medical practice plans</td>
<td>-</td>
<td>4,930,110</td>
<td>4,930,110</td>
<td>5,024,345</td>
<td></td>
</tr>
<tr>
<td>Research projects</td>
<td>76,063,180</td>
<td>-</td>
<td>76,063,180</td>
<td>83,996,310</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>-</td>
<td>536,290</td>
<td>536,290</td>
<td>686,493</td>
<td></td>
</tr>
<tr>
<td>Investment income (Note 5)</td>
<td>-</td>
<td>3,170,325</td>
<td>3,170,325</td>
<td>2,513,086</td>
<td></td>
</tr>
<tr>
<td>Amortization of deferred capital contributions</td>
<td>3,688,938</td>
<td>-</td>
<td>3,688,938</td>
<td>3,708,333</td>
<td></td>
</tr>
<tr>
<td></td>
<td>79,752,118</td>
<td>26,338,561</td>
<td>106,090,679</td>
<td>113,724,478</td>
<td></td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific programs</td>
<td>-</td>
<td>17,022,607</td>
<td>17,022,607</td>
<td>15,524,835</td>
<td></td>
</tr>
<tr>
<td>General research administration</td>
<td>-</td>
<td>3,168,703</td>
<td>3,168,703</td>
<td>3,022,419</td>
<td></td>
</tr>
<tr>
<td>Technology transfer program</td>
<td>-</td>
<td>346,848</td>
<td>346,848</td>
<td>263,791</td>
<td></td>
</tr>
<tr>
<td>Hospital services</td>
<td>-</td>
<td>3,708,972</td>
<td>3,708,972</td>
<td>3,546,735</td>
<td></td>
</tr>
<tr>
<td>Other research</td>
<td>-</td>
<td>900,392</td>
<td>900,392</td>
<td>826,003</td>
<td></td>
</tr>
<tr>
<td>Research ethics board</td>
<td>-</td>
<td>851,342</td>
<td>851,342</td>
<td>846,902</td>
<td></td>
</tr>
<tr>
<td>Research project costs (Note 7)</td>
<td>76,063,180</td>
<td>-</td>
<td>76,063,180</td>
<td>83,996,310</td>
<td></td>
</tr>
<tr>
<td>Amortization of capital assets</td>
<td>3,733,245</td>
<td>-</td>
<td>3,733,245</td>
<td>3,752,640</td>
<td></td>
</tr>
<tr>
<td></td>
<td>79,796,425</td>
<td>25,998,864</td>
<td>105,795,289</td>
<td>111,779,635</td>
<td></td>
</tr>
<tr>
<td><strong>EXCESS (DEFICIENCY) OF REVENUE OVER EXPENSES</strong></td>
<td>$ (44,307)</td>
<td>$ 339,697</td>
<td>$ 295,390</td>
<td>$ 1,944,843</td>
<td></td>
</tr>
</tbody>
</table>

See accompanying notes to the financial statements
## Statement of Changes in Net Assets

**year ended March 31, 2013**

<table>
<thead>
<tr>
<th>Externally Restricted</th>
<th>Internally Restricted (Note 11)</th>
<th>Invested in Capital Assets</th>
<th>Unrestricted</th>
<th>2013</th>
<th>2012 (Unaudited)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BALANCE, BEGINNING</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OF YEAR</td>
<td>$</td>
<td>-</td>
<td>$ 2,568,047</td>
<td>$ 712,761 $ 2,613,900 $ 5,894,708 $ 3,949,865</td>
<td></td>
</tr>
<tr>
<td>Excess (deficiency) of revenue over expenses</td>
<td>(44,307)</td>
<td>-</td>
<td>-</td>
<td>339,697</td>
<td>295,390</td>
</tr>
<tr>
<td>Transfer to internally restricted (Note 11)</td>
<td>-</td>
<td>295,390</td>
<td>-</td>
<td>(295,390)</td>
<td>-</td>
</tr>
<tr>
<td>Amortization of capital assets</td>
<td>3,733,245</td>
<td>-</td>
<td>(3,733,245)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Purchase of capital assets</td>
<td>(3,361,299)</td>
<td>3,361,299</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Deferred capital contributions received (Note 8)</td>
<td>3,361,299</td>
<td>-</td>
<td>(3,424,084)</td>
<td>62,785</td>
<td>-</td>
</tr>
<tr>
<td>Amortization of deferred capital contributions</td>
<td>(3,688,938)</td>
<td>-</td>
<td>3,688,938</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Repayment of loan payable</td>
<td>-</td>
<td>-</td>
<td>200,000</td>
<td>(200,000)</td>
<td>-</td>
</tr>
<tr>
<td>BALANCE, END OF YEAR</td>
<td>$</td>
<td>-</td>
<td>$ 2,863,437</td>
<td>$ 805,669 $ 2,520,992 $ 6,190,098 $ 5,894,708</td>
<td></td>
</tr>
</tbody>
</table>

See accompanying notes to the financial statements
## Statement of Cash Flows

**Year ended March 31, 2013**  
*(in thousands of dollars)*

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excess of revenue over expenses</td>
<td>$295,390</td>
<td>$1,944,843</td>
</tr>
<tr>
<td>Items not affecting cash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amortization of capital assets</td>
<td>3,733,245</td>
<td>3,752,639</td>
</tr>
<tr>
<td>Amortization of deferred capital contributions</td>
<td>(3,688,938)</td>
<td>(3,708,333)</td>
</tr>
<tr>
<td>Unrealized losses (gains) on investments (Note 5)</td>
<td>(1,425,350)</td>
<td>176,406</td>
</tr>
<tr>
<td>Changes in non-cash operating working capital items:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in due from The Ottawa Hospital Foundation</td>
<td>(977,280)</td>
<td>(1,130,342)</td>
</tr>
<tr>
<td>Decrease (increase) in prepaid expenses</td>
<td>35,888</td>
<td>(22,557)</td>
</tr>
<tr>
<td>Decrease (increase) in accounts receivable</td>
<td>4,611,221</td>
<td>(8,013,457)</td>
</tr>
<tr>
<td>Increase (decrease) in accounts payable and accrued liabilities</td>
<td>(11,662,779)</td>
<td>11,060,945</td>
</tr>
<tr>
<td>Increase (decrease) in due to The Ottawa Hospital</td>
<td>1,987,141</td>
<td>(32,301)</td>
</tr>
<tr>
<td>Increase (decrease) in unearned income</td>
<td>400,000</td>
<td>(680,379)</td>
</tr>
<tr>
<td>Increase in unexpended research project funding</td>
<td>4,828,943</td>
<td>1,240,809</td>
</tr>
<tr>
<td>Decrease in sick leave</td>
<td>-</td>
<td>(19,576)</td>
</tr>
<tr>
<td><strong>INVESTING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net increase in investments</td>
<td>(1,480,006)</td>
<td>(7,709,752)</td>
</tr>
<tr>
<td>Purchase of capital assets</td>
<td>(3,361,299)</td>
<td>(1,186,531)</td>
</tr>
<tr>
<td><strong>FINANCING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repayment of loan payable</td>
<td>(200,000)</td>
<td>(250,000)</td>
</tr>
<tr>
<td>Deferred capital contribution received</td>
<td>3,424,084</td>
<td>1,244,759</td>
</tr>
<tr>
<td><strong>NET CASH OUTFLOW</strong></td>
<td>(3,479,740)</td>
<td>(3,332,827)</td>
</tr>
<tr>
<td><strong>CASH, BEGINNING OF YEAR</strong></td>
<td>18,656,320</td>
<td>21,989,147</td>
</tr>
<tr>
<td><strong>CASH, END OF YEAR</strong></td>
<td>$15,176,580</td>
<td>$18,656,320</td>
</tr>
</tbody>
</table>

See accompanying notes to the financial statements
1. OBJECTIVES

The Ottawa Hospital Research Institute (the "Institute") is an independent health research facility closely affiliated with The Ottawa Hospital and the University of Ottawa, committed to excellence in the creation of scientific knowledge that contributes to the prevention, diagnosis, and treatment of human disease. The Institute was incorporated without share capital under the Ontario Corporations Act on December 5, 2000. It began operations on April 1, 2001 as a result of the combination of the Loeb Health Research Institute at The Ottawa Hospital and The Ottawa General Hospital Research Institute. On January 1, 2004, as a result of the integration of the Ottawa Regional Cancer Centre and The Ottawa Hospital, the clinical research activities of the Cancer Centre were absorbed into the Institute.

The Institute is a registered charity under paragraph 149(1)(f) of the Income Tax Act and is exempt from income taxes and may issue tax deductible receipts to donors. Furthermore, the Institute has approved research institute status for purposes of clause 37 (1)(a)(ii)(b) of the Act, whereby a donor is eligible for a Scientific Research and Experimental Development (SR&ED) tax credit in the year the contribution is made.

2. ADOPTION OF A NEW ACCOUNTING FRAMEWORK

During the year ended March 31, 2013, the Institute adopted the Canadian accounting standards for not-for-profit organizations (the "new standards") issued by the Canadian Institute of Chartered Accountants ("CICA") as set out in Part III of the CICA Handbook. The Institute also applies the standards for private enterprises in Part II of the CICA Handbook to the extent that Part II addresses topics not addressed in Part III. In accordance with Section 1501 of the CICA Handbook, First-time adoption by not-for-profit organizations ("Section 1501"), the date of transition to the new standards was April 1, 2011 and the Institute has presented an opening statement of financial position at the date of transition to the new standards. This opening statement of financial position is the starting point for the entity's accounting under the new standards. In its opening statement of financial position, under the recommendations of Section 1501, the Institute:

- recognized all assets and liabilities whose recognition is required by the new standards;
- did not recognize items as assets or liabilities if the new standards do not permit such recognition;
2. ADOPTION OF A NEW ACCOUNTING FRAMEWORK (Continued)

- reclassified items that it recognized previously as one type of asset, liability or component of net assets, but are recognized as a different type of asset, liability or component of net assets under the new standards; and

- applied the new standards in measuring all recognized assets and liabilities.

In accordance with the requirements of Section 1501, the accounting policies set out in Note 3 have been consistently applied to all comparative figures. The Institute has not applied any of the exemptions available under Section 1501, as the Institute determined there is no financial impact on the financial statements.

There were no significant changes as a result of the adoption of the new standards.

3. SIGNIFICANT ACCOUNTING POLICIES

The financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations and include the following significant accounting policies:

Basis of presentation

On the statement of financial position and the statement of operations, the externally restricted column presents the Institute’s assets, liabilities and results of operations related to its research activities that are funded by externally restricted research grants and contributions. The unrestricted column presents the Institute’s administrative and non-restricted research operations.

Revenue recognition

The Institute follows the deferral method of accounting.

The Institute generates revenue through contributions from external funding agencies and related parties. Contributions receivable are recorded at an estimated realizable value in the period in which the funding agreement is signed. Unrestricted contributions are recorded as revenue when they are received or receivable. Restricted contributions are recorded as deferred revenue and recognized as revenue when the related expenses are incurred.

Contributions restricted for the acquisition of capital assets are recorded as deferred capital contributions and recognized as revenue over the estimated useful life of the related capital assets.
3. **SIGNIFICANT ACCOUNTING POLICIES (Continued)**

*Revenue recognition (Continued)*

Interest and dividend revenue and realized gains and losses on investments are recognized in the period earned. Unrealized gains and losses on investments are recorded in the period in which they occur.

*Expenses*

The Institute classifies expenses on the statement of operations by function. Expenses are recognized in the year incurred and are recorded in the applicable function to which they are related. The Institute does not allocate expenses between functions after initial recognition.

*Cash*

Cash is recorded at fair value.

*Investments*

Investments are recorded at fair value, unrealized gains and losses on the fair value of investments are recognized as investment income in the statement of operations.

Shares in private companies acquired by the Institute in exchange for patent or license rights are recorded at nominal value when the fair value of the transaction is not determinable.

*Other financial instruments*

The due to The Ottawa Hospital Foundation, accounts receivable, accounts payable and accrued liabilities, loan payable, due to The Ottawa Hospital and sick leave liability are measured at amortized cost using the effective interest rate method.

*Capital assets*

Capital assets are stated at cost. Contributed equipment is recorded at fair value at the date of contribution. Amortization is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives of the assets are as follows:

<table>
<thead>
<tr>
<th>Asset</th>
<th>Useful Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer equipment</td>
<td>5 years</td>
</tr>
<tr>
<td>Furniture and fixtures</td>
<td>5 years</td>
</tr>
<tr>
<td>Buildings/portable</td>
<td>5 years</td>
</tr>
<tr>
<td>Laboratory equipment</td>
<td>5 - 10 years</td>
</tr>
<tr>
<td>Stem Cell and Vision Research floors</td>
<td>21 years</td>
</tr>
</tbody>
</table>
3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Capital assets (Continued)

Patents are recorded at nominal value and are not amortized.

Capital assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When the capital asset no longer has any long-term service potential, the excess of its net carrying amount over its residual value is expenses.

Foreign exchange

Transactions conducted in a foreign currency are translated into Canadian dollars at the exchange rate in effect at the date of the transaction. Assets and liabilities denominated in foreign currencies are translated at exchange rates in effect at year-end. Foreign exchange gains and losses are recorded in the statement of operations.

Use of estimates

The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from these estimates. The most significant estimates used in preparing these financial statements include the fair value of investments, the estimated useful lives of capital assets, the amount of accrued liabilities and the allowance for doubtful accounts. These estimates are reviewed annually and, as adjustments become necessary, they are reported in the periods in which they become known.

4. RELATED ENTITIES

Related party transactions are in the normal course of operations and are measured at the exchange amount which is the amount of consideration established and agreed to by the related parties. The Institute has no control over these related parties.

The Ottawa Hospital

The Ottawa Hospital acts as paymaster for the Institute. The Institute has an amount due to The Ottawa Hospital of $3,838,252 (March 31, 2012 - $1,851,111; April 1, 2011 - $1,883,412). This balance represents the difference between funds deposited at the Hospital and disbursements made on behalf of the Institute at year-end.
4. RELATED ENTITIES (Continued)

The Ottawa Hospital (Continued)

The Ottawa Hospital provided the Institute with grants as follows:

<table>
<thead>
<tr>
<th></th>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>General operating</td>
<td>$4,352,196</td>
<td>$4,805,775</td>
</tr>
<tr>
<td>Specific purpose</td>
<td>250,000</td>
<td>376,800</td>
</tr>
<tr>
<td></td>
<td>$4,602,196</td>
<td>$5,182,575</td>
</tr>
</tbody>
</table>

The Ottawa Hospital Foundation

The Foundation provides administrative and research funding to the Institute. During the year, the Foundation contributed the following:

<table>
<thead>
<tr>
<th></th>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted endowment fund interest</td>
<td>$2,705,471</td>
<td>$2,677,401</td>
</tr>
<tr>
<td>Restricted endowment fund interest for research projects</td>
<td>38,020</td>
<td>155,968</td>
</tr>
<tr>
<td>Unrestricted research and salary funding</td>
<td>2,128,021</td>
<td>1,861,303</td>
</tr>
<tr>
<td>Restricted research project funding</td>
<td>3,823,663</td>
<td>1,592,885</td>
</tr>
<tr>
<td>Deferred contributions relating to capital assets</td>
<td>248,878</td>
<td>886,956</td>
</tr>
<tr>
<td></td>
<td>$8,944,053</td>
<td>$7,174,513</td>
</tr>
</tbody>
</table>

At year-end, $4,836,322 (March 31, 2012 - $3,859,042; April 1, 2011 - $2,728,700) of these amounts were receivable from the Foundation.
4. RELATED ENTITIES (Continued)

The Ottawa Hospital Foundation (continued)

At March 31, 2013, the Foundation manages funds in the amount of $41,217,045 (March 31, 2012 - $43,942,419; April 1, 2011 - $50,832,318), which are designated as The Ottawa Hospital Research Institute Endowment Funds. While these funds have been designated to the Institute they are legally the assets of the Foundation. Of this amount, $956,568 (March 31, 2012 - $942,678; April 1, 2011 - $995,747) is restricted for the Clinical Epidemiology Unit Director's Research Chair, and $5,627,254 (March 31, 2012 - $10,400,342; April 1, 2011 - $15,689,701) is restricted for the Sprott Endowment for Stem Cell Research.

The University of Ottawa

The University of Ottawa contributed $1,222,792 (2012 - $1,368,843) during the year to the Institute for salary support.

At March 31, 2013, endowment funds in the amount of $1,217,562 (March 31, 2012 - $1,155,216; April 1, 2011 - $1,163,367) for the Clinical Epidemiology Unit Director's Research Chair, $1,586,003 (March 31, 2012 - $1,505,394; April 1, 2011 - $1,516,623) for the Dr. J. David Grimes Research Chair and $1,972,072 (March 31, 2012 - $1,870,188; April 1, 2011 - 1,882,480) for the Neuroscience Research Institute Chair are held by the University of Ottawa. During the year, the Institute received $174,954 (2012 - $172,088) interest on these endowments.

The University provides premises and related maintenance and repairs to the Institute’s on-site researchers at no charge. These amounts are not included in these financial statements.

Loan payable

The University of Ottawa provided a loan to the Institute for the purpose of funding the construction of the Vision floor. The loan from the University of Ottawa is non-interest-bearing and was repayable starting in 2011, as agreed, if fundraising and/or grant submissions are not successful. The final payment of the loan was paid during the 2013 fiscal year, leaving a balance at March 31, 2013 of $NIL (March 31, 2012 - $200,000; April 1, 2011 - $450,000).
5. INVESTMENTS

The following table presents the fair values of the Institute’s investments:

<table>
<thead>
<tr>
<th></th>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fair Value</td>
<td>Cost</td>
</tr>
<tr>
<td>Money market funds</td>
<td>$109,700</td>
<td>$109,700</td>
</tr>
<tr>
<td>Bonds / Fixed income funds</td>
<td>32,711,242</td>
<td>32,654,156</td>
</tr>
<tr>
<td>Mutual funds / Pooled funds</td>
<td>16,804,707</td>
<td>14,951,869</td>
</tr>
<tr>
<td>Shares in private companies</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td><strong>$49,625,650</strong></td>
<td><strong>$47,715,726</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>April 1, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fair Value (Unaudited)</td>
</tr>
<tr>
<td>Money market funds</td>
<td>$5,822,591</td>
</tr>
<tr>
<td>Bonds / Fixed income funds</td>
<td>23,421,373</td>
</tr>
<tr>
<td>Mutual funds / Pooled funds</td>
<td>9,942,983</td>
</tr>
<tr>
<td>Shares in private companies</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td><strong>$39,186,948</strong></td>
</tr>
</tbody>
</table>

The Institute holds shares in private companies that were received in exchange for an amendment to a patent/licence agreement previously negotiated and in other cases, patent or license agreements to be negotiated. These shares do not give the Institute the ability to significantly influence or exercise control over these private companies. The shares are recorded in these financial statements at a nominal value as the value of the consideration given or received could not be determined. The fair value of these shares in private companies is not determinable.
The bonds/fixed income funds have interest rates of 1.5% to 12.2% (March 31, 2012 - 1.5% to 12.2%; April 1, 2011 - 1.75% to 11%) and maturity dates ranging from May 2013 to November 2052 (March 31, 2012 - April 2012 to November 2050; April 1, 2011 - March 2012 to November 2040).

The following table presents the breakdown of the investment revenue on investments held by the Institute:

<table>
<thead>
<tr>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Realized gains on investments</td>
<td>$1,479,767</td>
</tr>
<tr>
<td>Unrealized gains (losses) on investments</td>
<td>1,425,350</td>
</tr>
<tr>
<td>Interest</td>
<td>265,208</td>
</tr>
<tr>
<td>Accrued interest</td>
<td>-</td>
</tr>
<tr>
<td>Foreign exchange gain</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$3,170,325</strong></td>
</tr>
</tbody>
</table>

6. CAPITAL ASSETS

<table>
<thead>
<tr>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
<th>April 1, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost</td>
<td>Accumulated Amortization</td>
<td>Net Book Value</td>
</tr>
<tr>
<td>Computer equipment</td>
<td>$2,334,452</td>
<td>$2,333,783</td>
</tr>
<tr>
<td>Furniture and fixtures</td>
<td>2,223,082</td>
<td>1,980,122</td>
</tr>
<tr>
<td>Buildings/Portable Laboratory equipment</td>
<td>409,970</td>
<td>409,970</td>
</tr>
<tr>
<td>Stem Cell and Vision Research floors</td>
<td>39,202,573</td>
<td>30,276,171</td>
</tr>
<tr>
<td>Patents</td>
<td>24,855,382</td>
<td>8,188,599</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$69,025,460</strong></td>
<td><strong>$43,188,645</strong></td>
</tr>
</tbody>
</table>
6. CAPITAL ASSETS (Continued)

Cost and accumulated amortization of capital assets at March 31, 2012 amounted to $68,789,732 and $42,580,971, respectively (April 1, 2011 - $67,193,227 and $38,418,358)

7. UNEXPENDED RESEARCH PROJECT FUNDING

Unexpended research project funding represents amounts received by the Institute which will be used in subsequent periods on active research projects. Changes in the unexpended research project funding balance are as follows:

<table>
<thead>
<tr>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Unaudited)</td>
</tr>
<tr>
<td></td>
<td>(Note 2)</td>
</tr>
<tr>
<td>Balance, beginning of year</td>
<td>$ 63,045,498</td>
</tr>
<tr>
<td>Amounts received in the current period</td>
<td>84,316,207</td>
</tr>
<tr>
<td></td>
<td>147,361,705</td>
</tr>
<tr>
<td>Less</td>
<td>148,286,567</td>
</tr>
<tr>
<td>Research project costs</td>
<td>(76,063,180)</td>
</tr>
<tr>
<td>Amount transferred to deferred capital contributions</td>
<td>(3,424,084)</td>
</tr>
<tr>
<td></td>
<td>(1,244,759)</td>
</tr>
<tr>
<td>Balance, end of year</td>
<td>$ 67,874,441</td>
</tr>
</tbody>
</table>

8. DEFERRED CAPITAL CONTRIBUTIONS

<table>
<thead>
<tr>
<th>March 31, 2013</th>
<th>March 31, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Unaudited)</td>
</tr>
<tr>
<td></td>
<td>(Note 2)</td>
</tr>
<tr>
<td>Balance, beginning of year</td>
<td>$ 25,296,000</td>
</tr>
<tr>
<td>Additions</td>
<td>3,424,084</td>
</tr>
<tr>
<td>Amortization</td>
<td>(3,688,938)</td>
</tr>
<tr>
<td></td>
<td>(3,708,333)</td>
</tr>
<tr>
<td>Balance, end of year</td>
<td>$ 25,031,146</td>
</tr>
</tbody>
</table>

$ 25,031,146 $ 25,031,146
9. SICK LEAVE

Accrued sick leave relates to the accumulated balance for compensated absences for employees of the former Ottawa Civic Hospital before amalgamation. Under the amalgamation agreement, this balance has been frozen and will be paid out to employees upon their departure from the Institute and related entities.

10. COMMITMENTS

The Institute is committed to providing contributions to The Ottawa Hospital in respect of the construction or fit up of various buildings or floors as follows:

<table>
<thead>
<tr>
<th>Commitment</th>
<th>Commitment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Centre</td>
<td>$ 5.22 million</td>
</tr>
<tr>
<td>Regenerative Medicine Floors</td>
<td>1.84 million</td>
</tr>
<tr>
<td>The Centre for Practice Changing Research</td>
<td>1.16 million</td>
</tr>
</tbody>
</table>

At year-end, the Institute has secured external funding for these commitments in the amount of $8.22 million, the timing of the distribution of these commitments had not yet been determined.

11. INTERNALLY RESTRICTED NET ASSETS

Internally restricted net assets are comprised of the Equalization Fund

The Equalization Fund was established by the Board of Directors to provide the Institute with stable investment income for short and long-term budget planning. On an annual basis Management along with the Investment managers set a budgeted return on investments, which is approved by the Board. Actual investment income in excess of the budgeted amount, to the maximum of net income for the year, is transferred to the Equalization Fund. When actual investment income is less than the budgeted amount the difference, to the maximum of the balance of the Equalization Fund, is transferred to the unrestricted fund from the Equalization Fund. During the year, $295,390 (2012 - $713,086) was transferred to the Equalization Fund.
12. **PENSION PLAN**

Substantially all of the full-time employees of the Institute are members of the Hospitals of Ontario Pension Plan (the "Plan"), which is a multi-employer defined benefit pension plan available to all eligible employees of the participating members of the Ontario Hospital Association. Plan members will receive benefits based on the length of service and on the average of annualized earnings during the five consecutive years prior to retirement, termination or death that provide the highest earnings.

Pension assets consist of investment grade securities. Market and credit risk on these securities are managed by the Plan by placing plan assets in trust and through the Plan investment policy.

Pension expense is based on Plan management’s best estimates, in consultation with its actuaries, of the amount, together with the 1.3% of salary contributed by employees, required to provide a high level of assurance that benefits will be fully represented by fund assets at retirement, as provided by the Plan. The funding objective is for employer contributions to the Plan to remain a constant percentage of employees’ contributions.

Variances between actuarial funding estimates and actual experience may be material and any differences are generally to be funded by the participating members. The most recent actuarial valuation of the Plan as at December 31, 2012 indicates the Plan is fully funded. Contributions to the Plan made during the year by the Institute on behalf of its employees amounted to $2,182,203 (2012 - $2,219,932) and are included in the statement of operations.

13. **FINANCIAL INSTRUMENTS**

The Institute’s financial instruments consist of cash, accounts receivable, due from The Ottawa Hospital Foundation, investments, accounts payable and accrued liabilities, loan payable, due to The Ottawa Hospital and sick leave.

The carrying values of accounts receivable, due from The Ottawa Hospital Foundation, accounts payable and accrued liabilities, loan payable and due to The Ottawa Hospital approximate their fair values due to the relatively short periods to maturity of the instruments.

The fair value of investments is disclosed in Note 5. The fair value of sick leave is not determinable.

The Institute’s exposure to interest rate risk includes all cash, investments, bonds and money market funds. Foreign currency risk exposure is limited to international mutual funds of $8,236,138 (March 31, 2012 - $5,196,226; April 1, 2011 - $3,574,685).
13. **FINANCIAL INSTRUMENTS (Continued)**

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party to discharge an obligation. The Institute’s main exposure comes from its investments and amounts receivable. Management does not believe it is exposed to any significant credit risk due as receivables are primarily from related parties and government organizations; investments are diversified as disclosed in Note 5.

14. **CAPITAL DISCLOSURES**

The Institute considers its capital to consist of its unrestricted net assets, internally restricted net assets and its net assets invested in capital assets. The Institute’s overall objective with its capital is to fund capital asset acquisitions, ongoing operations and future health research. The purpose of internally restricted net assets is to provide stability and funding for unforeseen events. The purpose of the net assets invested in capital assets is to fund the past acquisition of capital assets required for operation purposes.

The Institute is not subject to externally imposed capital requirements and its overall strategy with respect to capital remains unchanged from the year ended March 31, 2012.